These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21183396)

  • 1. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
    Field HJ; Biswas S
    Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
    Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
    Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
    Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
    Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant.
    Sukla S; Biswas S; Birkmann A; Lischka P; Ruebsamen-Schaeff H; Zimmermann H; Field HJ
    Antiviral Res; 2010 Jul; 87(1):67-73. PubMed ID: 20420855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
    Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
    J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
    Biswas S; Jennens L; Field HJ
    Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New antiviral drugs that target herpesvirus helicase primase enzymes.
    Kleymann G
    Herpes; 2003 Aug; 10(2):46-52. PubMed ID: 14577954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
    Biswas S; Field HJ
    Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
    Biswas S; Sukla S; Field HJ
    Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
    Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
    Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
    Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
    Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
    Kleymann G
    Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
    Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
    J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
    Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSV antivirals - current and future treatment options.
    Birkmann A; Zimmermann H
    Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
    Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
    Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
    Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.